Dr. Govindan on the Future of EGFR-Mutant NSCLC

Ramaswamy Govindan, MD
Published: Thursday, May 11, 2017



Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well. 
 
SELECTED
LANGUAGE


Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x